Let's review the charts and indicators.
The clinical stage company sees its shares climb after announcing some significant news during this week's J.P. Morgan Healthcare Conference.
It's likely the deal goes through, but I don't believe that attempting to take advantage of FIT's current 11% discount is worth the risk.
TG Therapeutics and Exelixis could find themselves on the shopping lists of other companies.
A document filed with the SEC reveals the behind-the-scenes competition between Alphabet and another suitor for the hand of the smartwatch maker.
The planned acquisition of The Medicines Company by Novartis spurs prospects of other deals in the drug business.
During a talk with TheStreet, CFO Glenn Schiffman talked about IAC's reasons for holding off on an ANGI Homeservices spinoff, as well as the differences between private and public valuations.
Let's see whether FL is a good fit for investors right now.
We're seeing lots of companies snapping up their peers, and the market is applauding.
With the potential TD Ameritrade deal, clearly E*Trade will not be 'talking to Chuck.'
Also, Fed Chairman Powell says there are no plans for a U.S. digital currency (for now), plus Tesla's electric pickup.
With Carl Icahn involved on both sides, we can expect him to lean heavily on both Boards to come to an agreement.
If tempted, don't forget HPQ will report the firm's fourth quarter performance next Tuesday.
HP's board of directors has rejected Xerox's takeover bid, but the door has not been closed on a potential combination.
Traders would do well to find another stock to trade right now.
After the strong run of homebuilders in 2019, the sector simply isn't as oversold as it was to start the year.
I see upside back to above $70 regardless of whether the company gets taken private.
Things that make you go hmmm ahead of the Viacom merger.
The media giant's technical signals hint at an upside move in its stock.
FHN announced earlier this week it is merging with Iberia Bank.
I'm all in favor of mergers and acquisitions -- the more we get, the higher the stock market goes -- but I am not in favor of making conclusions based on tips about deals.
Reports of two potentially major buyouts show the risks of late-cycle corporate bond investing.
Let others wait and see if someone comes in with a better offer than Alphabet's bid for Fitbit; this value investor is taking his profit and leaving the table.
The buyout offer for Tiffany & Co. from Louis Vuitton's parent could spark more deals; this trio of sagging stocks could make for targets.
The maker of wearable fitness devices has seen its stock sprint higher on the buyout news after languishing this summer near multi-year lows.
These stocks are priced for total imperfection. That's just what you want.
Biogen, Novartis and Bristol-Myers Squibb are among the drugmakers that gave investors reasons for cheer on Tuesday.
Let's review the charts and indicators to see what they are showing today.
M&A activity has generally slowed.
Black-market vaping has made the entire cannabis group toxic.